Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mimbari who wrote (12197)	7/9/2013 6:45:10 AM
From: NTTG	1 Recommendation Recommended By Pogeu Mahone Read Replies (2) \| Respond to of 13111

A consensus of opinions suggests that investors should have a healthy dose of skepticism around PVCT business and clinical development practices. If you call that a 'chip on both shoulders', so be it. Time is already telling which view is correct, and there are abundant comparative examples (which I am banned from discussing on this board) of companies taking the right steps for investors to benchmark PVCT against. I have yet to encounter a PVCT supporter who can provide a solid example of business success using the path PVCT has taken, I am guessing you can not either. I don't care about your 'credentials', just your ability to make a productive analytic point that can help clarify the investment landscape...still waiting